I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

HCWB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 49.90%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

HCW Biologics Insider Trading History Chart

HCW Biologics Share Price & Price History

^$0.77

▲ +0.06 (8.45%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Financial Prophecy

From Porter & Company | Ad

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

HCW Biologics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2023	Hing C Wong	CEO	Buy	1,800	$2.08	$3,744.00	15,314,868
9/13/2023	Gary M Winer	Director	Buy	546	$2.05	$1,119.30	15,959
9/13/2023	Rebecca Byam	CFO	Buy	5,000	$2.10	$10,500.00	573,946
9/11/2023	Gary M Winer	Director	Buy	99	$2.05	$202.95	14,913
9/11/2023	Rebecca Byam	CFO	Buy	5,000	$2.05	$10,250.00	563,946
9/8/2023	Rebecca Byam	CFO	Buy	5,000	$2.02	$10,100.00	558,946
9/7/2023	Gary M Winer	Director	Buy	63	$1.95	$122.85	14,813
9/6/2023	Rebecca Byam	CFO	Buy	5,000	$1.95	$9,750.00	548,946
9/5/2023	Gary M Winer	Director	Buy	400	$1.75	$700.00	14,750
6/9/2023	Rebecca Byam	CFO	Buy	20,000	$2.06	$41,200.00	543,946
6/8/2023	Lee Flowers	SVP	Buy	10,000	$2.16	$21,600.00	111,308
6/7/2023	Rebecca Byam	CFO	Buy	20,000	$2.03	$40,600.00	519,250
6/5/2023	Rebecca Byam	CFO	Buy	20,000	$1.67	$33,400.00	480,188
6/1/2023	Hing C Wong	CEO	Buy	800	$1.62	$1,296.00	15,312,268
5/30/2023	Gary M Winer	Director	Buy	850	$1.52	$1,292.00	13,850
5/30/2023	Hing C Wong	CEO	Buy	3,000	$1.55	$4,650.00	15,309,468
5/26/2023	Rebecca Byam	CFO	Buy	20,000	$1.66	$33,200.00	460,188
5/24/2023	Rebecca Byam	CFO	Buy	20,000	$1.61	$32,200.00	420,188
5/22/2023	Rebecca Byam	CFO	Buy	33,450	$1.53	$51,178.50	395,152
9/14/2022	Rebecca Byam	CFO	Buy	15,000	$2.58	$38,700.00	327,952
9/12/2022	Rebecca Byam	CFO	Buy	15,000	$2.65	$39,750.00	297,952
9/8/2022	Hing C Wong	CEO	Buy	4,000	$2.67	$10,680.00	15,300,468
8/29/2022	Rebecca Byam	CFO	Buy	10,000	$2.57	$25,700.00	265,752
8/26/2022	Rebecca Byam	CFO	Buy	10,000	$2.54	$25,400.00	255,752
8/24/2022	Rebecca Byam	CFO	Buy	50,000	$2.50	$125,000.00	205,452
6/13/2022	Rebecca Byam	CFO	Buy	7,596	$2.08	$15,799.68	96,596
6/10/2022	Gary M Winer	Director	Buy	1,500	$2.13	$3,195.00	13,000
6/9/2022	Hing C Wong	CEO	Buy	2,000	$2.25	$4,500.00	15,284,948
6/8/2022	Gary M Winer	Director	Buy	1,000	$2.27	$2,270.00	10,500
6/6/2022	Gary M Winer	Director	Buy	1,000	$2.13	$2,130.00	8,500
6/2/2022	Rick S Greene	Director	Buy	4,800	$2.09	$10,032.00	8,411
12/6/2021	Jin-An Jiao	VP	Buy	10,000	$2.42	$24,200.00

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

SEC Filings (Institutional Ownership Changes) for HCW Biologics (NASDAQ:HCWB)

2.96% of HCW Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HCW Biologics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/2/2024	Pullen Investment Management LLC	85,116	$0.15M	0.1%	N/A	0.225%
2/9/2024	Avantax Planning Partners Inc.	179,541	$0.22M	0.0%	N/A	0.499%
2/9/2023	HighTower Advisors LLC	269,869	$0.52M	0.0%	+19.6%	0.752%
11/15/2021	HighTower Advisors LLC	14,000	$45K	0.0%	N/A	0.039%

Data available starting January 2016

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Today's Range

Now: $0.77

$0.63

$0.79

50 Day Range

MA: $0.53

$0.29

$1.24

52 Week Range

Now: $0.77

$0.28

$2.52

Volume

2,072,587 shs

Average Volume

28,803,408 shs

Market Capitalization

$29.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Who are the company insiders with the largest holdings of HCW Biologics?: HCW Biologics' top insider investors include:
Hing C Wong (CEO)
Rebecca Byam (CFO)
Lee Flowers (SVP)
Gary M Winer (Director)
Learn More about top insider investors at HCW Biologics.